AUGS 2012 - Evaluation of the quality of life improvements at six months in subjects with overactive bladder randomized to Interstim® therapy implant versus standard medical therapy - Session Highlights

CHICAGO, IL USA (UroToday) - Changes in QoL were assessed as part of a randomized trial involving 147 patients from 38 medical centers (93% were female with a mean age of 58.7 years).

The study showed significant improvement in QoL at six months for patients receiving the Interstim implant versus those receiving standard medical therapy. Of the 51 patients receiving the Interstim implant, nine failed stage 1 of the procedure and 10 chose not to continue with the therapy.

Presented by J. Mangel* at the annual American Urogynecologic Society (AUGS) 33rd Annual Scientific Meeting - October 3 - 6, 2012 - Hilton Chicago - Chicago, Illinois USA

*MetroHealth Medical Center, Cleveland, OH USA


 Reported for UroToday by Karen Roberts, Medical Editor


augs thumbThis year’s 33rd Annual Meeting of the American Urogynecologic Society (AUGS) is the largest gathering to date with an increase in abstracts (346) and video presentations (41). AUGS reports an overall membership increase at 1,500 members.

SUFU MyBladder app